HA
Therapeutic Areas
CytoSorbents Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CytoSorb® / CytoSorb 300® | Reduction of elevated cytokines, bilirubin, myoglobin; Removal of Ticagrelor/Rivaroxaban during cardio-pulmonary bypass surgery | Approved (CE Mark) |
| DrugSorb-ATR® | Removal of Ticagrelor and Rivaroxaban (antiplatelet/anticoagulant drugs) in cardiothoracic surgery | Investigational |
| PuriFi | Hemoperfusion system to enable independent CytoSorb® therapy | Device Development |
| ECOS-300CY | Use with Ex Vivo Organ Perfusion (EVOP) to manage inflammatory processes in donor organs | Device Development |
| VetResQ | Veterinary critical-care applications | Commercial |
Leadership Team at CytoSorbents
PP
Phillip P. Chan, MD, PhD
Chief Executive Officer
EN
Efthymios N. Deliargyris, MD, FACC, FESC, FSCAI
Chief Medical Officer
PJ
Peter J. Mariani
Chief Financial Officer
DW
Daniel Wendt, FECTS, FACS, MHBA
Vice President Medical Cardio-Vascular
DJ
Dr. Jörg Scheier
Vice President Medical Critical Care
MB
Michael Bator
Chairman of the Board
ER
Edward R. Jones MD, MBA
Board of Directors, Clinical Professor of Medicine, Temple University Hospital
AD
Alan D. Sobel MS, CPA
Board of Directors, Managing Member, Sobel & Co., LLC